A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy-Reference-Cited by-同舟云学术

A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy

Published:2016-09 Issue: Volume:99 Page:186-193
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Yoh Kiyotaka,Hosomi Yukio^ORCID,Kasahara Kazuo,Yamada Kazuhiko,Takahashi Toshiaki,Yamamoto Nobuyuki,Nishio Makoto,Ohe Yuichiro,Koue Toshiko,Nakamura Takashi,Enatsu Sotaro,Lee Pablo,Ferry David,Tamura Tomohide,Nakagawa Kazuhiko

Funder

Eli Lilly Japan K.K.

Eli Lilly Japan K.K. ProScribe’s services

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. Clinical advances in the development of novel VEGFR2 inhibitors;Fontanella;Ann. Transl. Med.,2014

2. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2;Spratlin;J. Clin. Oncol.,2010

3. Regard trial investigators, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international randomised, multicentre, placebo-controlled, phase 3 trial;Fuchs;Lancet,2014

4. Rainbow Study Group, Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind randomised phase 3 trial;Wilke;Lancet Oncol.,2014

5. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Occurrence of respiratory and urinary tract infections in patients treated with docetaxel compared with afatinib based on a health insurance claims database in Japan;International Journal of Clinical Pharmacy;2024-08-03

2. Influence of Previous Therapy for Neutropenia Caused by Combination Therapy of Ramucirumab and Docetaxel;Cancers;2024-05-30

3. Progression-free survival estimation of docetaxel-based second-line treatment for advanced non-small cell lung cancer: a pooled analysis from 18 randomized control trials;Frontiers in Oncology;2024-05-14

4. Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients;Targeted Oncology;2024-03-11

5. Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051;Scientific Reports;2024-02-15